Company record · TECH · Biological Products, (No Diagnostic Substances)
BIO-TECHNE Corp
We could not establish BIO-TECHNE Corp's principal financial officer from its filings: From the 10-K filed 2026-08-24: title "Chief Financial Officer (principal financial officer and principal accounting officer)" is not a verbatim CFO or principal financial officer title.
The record holds BIO-TECHNE Corp's 10-K filed August 24, 2026, where no CFO signature could be established, and no Form 8-K CFO change.
The CFO seat
Computed from the records below: a move filed on or after the 10-K replaces the 10-K's signature.
| Status | Not established |
|---|---|
| Basis | Not established from the 10-K filed August 24, 2026 |
Seat timeline
1Every verified record for this seat, newest first, dated as the filing states it.
2026-08-2410-K signature
CFO signature not established from the annual report
10-K filed August 24, 2026 · sec.gov
Company
| Ticker | TECH |
|---|---|
| SEC CIK | 0000842023 |
| Industry (SIC) | Biological Products, (No Diagnostic Substances) (2836) |
Same industry on the record
8Other companies the roster files under SIC “Biological Products, (No Diagnostic Substances)”.
Allogene Therapeutics, Inc.ALLO
Departure disclosed · Geoffrey Parker · no successor on the record yet
Armata Pharmaceuticals, Inc.ARMP
CFO: David House · effective July 17, 2026
Atara Biotherapeutics, Inc.ATRA
Interim CFO: Kevin G. Sarney · effective June 26, 2026
Caribou Biosciences, Inc.CRBU
Departure disclosed · Sriram Ryali · no successor on the record yet
ImageneBio, Inc.IMA
CFO: Yanina Grant-Huerta · effective July 20, 2026
IRulya Therapeutics Inc.QNCX
CFO: John Militello · effective not stated in the source
Jasper Therapeutics, Inc.JSPR
Interim CFO: Jeet Mahal · effective October 9, 2026
Kalaris Therapeutics, Inc.KLRS
CFO: Liisa Bayko · effective July 20, 2026
This record covers what the tracked filings state; it is not a complete history of the company's finance leadership. Spot an error? Send a correction.